Literature DB >> 1716089

A cell culture assay for compounds which inhibit hepatitis B virus replication.

B E Korba1, G Milman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1716089     DOI： 10.1016/0166-3542(91)90068-3

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  25 in total

Review 1.  Mitochondrial injury. Lessons from the fialuridine trial.

Authors:  P Honkoop; H R Scholte; R A de Man; S W Schalm
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

2.  An experiment on standardized cell culture assay in assessing the activities of Composite Artemisia Capillaris Tablets against hepatitis B virus replication in vitro.

Authors:  Jin Han; Yan-ling Zhao; Li-mei Shan; Feng-jiao Huang; Xiao-he Xiao
Journal:  Chin J Integr Med       Date:  2005-03       Impact factor: 1.978

3.  Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.

Authors:  R W King; S K Ladner; T J Miller; K Zaifert; R B Perni; S C Conway; M J Otto
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

4.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.

Authors:  B E Korba; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.

Authors:  William E Delaney; Adrian S Ray; Huiling Yang; Xiaoping Qi; Shelly Xiong; Yuao Zhu; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.

Authors:  Nobuyo Higashi-Kuwata; Sanae Hayashi; Debananda Das; Satoru Kohgo; Shuko Murakami; Shin-Ichiro Hattori; Shuhei Imoto; David J Venzon; Kamalendra Singh; Stefan G Sarafianos; Yasuhito Tanaka; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

8.  Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells.

Authors:  Yong Guo; Hongyan Guo; Liang Zhang; Hongying Xie; Xin Zhao; Fangxun Wang; Ze Li; Yahui Wang; Shiliang Ma; Jiaping Tao; Weixing Wang; Yuxiang Zhou; Weiping Yang; Jing Cheng
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

9.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.

Authors:  M T Paff; D R Averett; K L Prus; W H Miller; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.